(1.03%) 5 180.74 points
(0.46%) 38 852 points
(1.19%) 16 349 points
(0.32%) $78.73
(-1.37%) $2.17
(0.05%) $2 332.40
(-0.02%) $27.61
(0.79%) $972.55
(0.06%) $0.929
(0.17%) $10.84
(0.06%) $0.796
(0.01%) $91.35
2.68% $ 46.32
@ $44.56
Emitido: 3 may 2024 @ 15:45
Retorno: 3.95%
Señal anterior: may 3 - 13:02
Señal anterior:
Retorno: 1.03 %
Live Chart Being Loaded With Signals
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer...
Stats | |
---|---|
Volumen de hoy | 611 332 |
Volumen promedio | 1.17M |
Capitalización de mercado | 3.43B |
EPS | $-1.450 ( 2024-05-02 ) |
Próxima fecha de ganancias | ( $-1.170 ) 2024-07-31 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -8.99 |
ATR14 | $1.659 (3.59%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Ashar Bhavesh | Sell | 1 824 | Common Stock |
2024-02-16 | Pichl Daniel | Buy | 15 000 | Common Stock |
2024-02-16 | Pichl Daniel | Sell | 15 000 | Common Stock |
2024-02-16 | Pichl Daniel | Sell | 15 000 | Stock Option (Right to Buy) |
2024-02-02 | Ashar Bhavesh | Sell | 1 089 | Common Stock |
INSIDER POWER |
---|
26.24 |
Last 99 transactions |
Buy: 2 487 277 | Sell: 1 935 911 |
Volumen Correlación
Springworks Therapeutics Correlación
10 Correlaciones Más Positivas | |
---|---|
PAE | 0.92 |
SY | 0.918 |
TIL | 0.917 |
CLBT | 0.916 |
FXCO | 0.915 |
SLN | 0.914 |
SCR | 0.914 |
CMPO | 0.914 |
TNYA | 0.913 |
ALGM | 0.911 |
10 Correlaciones Más Negativas | |
---|---|
BFRI | -0.916 |
TUEM | -0.915 |
VALN | -0.911 |
SVOK | -0.909 |
RTPY | -0.901 |
NAKD | -0.9 |
CYTO | -0.897 |
RMRM | -0.896 |
PROC | -0.895 |
LCAP | -0.883 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Springworks Therapeutics Correlación - Moneda/Commodity
Springworks Therapeutics Finanzas
Annual | 2023 |
Ingresos: | $5.45M |
Beneficio Bruto: | $5.03M (92.25 %) |
EPS: | $-5.15 |
FY | 2023 |
Ingresos: | $5.45M |
Beneficio Bruto: | $5.03M (92.25 %) |
EPS: | $-5.15 |
FY | 2022 |
Ingresos: | $6.15M |
Beneficio Bruto: | $4.25M (69.16 %) |
EPS: | $-5.14 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-4.02 |
Financial Reports:
No articles found.
Springworks Therapeutics
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico